Sonia Candamio

697 total citations
22 papers, 488 citations indexed

About

Sonia Candamio is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sonia Candamio has authored 22 papers receiving a total of 488 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 9 papers in Cancer Research and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sonia Candamio's work include Colorectal Cancer Treatments and Studies (15 papers), Cancer Genomics and Diagnostics (9 papers) and Cancer Treatment and Pharmacology (6 papers). Sonia Candamio is often cited by papers focused on Colorectal Cancer Treatments and Studies (15 papers), Cancer Genomics and Diagnostics (9 papers) and Cancer Treatment and Pharmacology (6 papers). Sonia Candamio collaborates with scholars based in Spain and Palestinian Territory. Sonia Candamio's co-authors include Alicia Abalo, Francisca Vázquez, Rafael López‐López, Mar Iglesias, Daniel L. Edelstein, María Vieito, Laura Visa, Joan Albanell, Joana Vidal and Clara Montagut and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and British Journal of Cancer.

In The Last Decade

Sonia Candamio

21 papers receiving 485 citations

Peers

Sonia Candamio

ONCOL

PFM

PRM

Joana Vidal Spain

Yuji Shimoda Japan

María Teresa Sanz Casla Spain

Clarence Eng United States

Rosario Alfonso Spain

Matilde Lambiase Italy

Marion Zitt Austria

Roxana Azimi United States

C. Cebotaru Romania

Marta Vismara Italy

Joana Vidal Spain

Sonia Candamio

381 ×1.1

ONCOL

364 ×1.2

262 ×1.5

PFM

174 ×1.1

PRM

121 ×1.1

Citations per year, relative to Sonia Candamio Sonia Candamio (= 1×) peers Joana Vidal

Countries citing papers authored by Sonia Candamio

Since Specialization

Citations

This map shows the geographic impact of Sonia Candamio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sonia Candamio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sonia Candamio more than expected).

Fields of papers citing papers by Sonia Candamio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sonia Candamio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sonia Candamio. The network helps show where Sonia Candamio may publish in the future.

Co-authorship network of co-authors of Sonia Candamio

This figure shows the co-authorship network connecting the top 25 collaborators of Sonia Candamio. A scholar is included among the top collaborators of Sonia Candamio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sonia Candamio. Sonia Candamio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fernández, Mercedes Salgado, et al.. (2024). Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group. Targeted Oncology. 19(4). 565–573. 1 indexed citations

Brozos-Vázquez, Elena, Ramón Manuel Lago‐Lestón, Ana Fernández Montés, et al.. (2023). Clinicopathological Profiles Associated with Discordant RAS Mutational Status between Liquid and Tissue Biopsies in a Real-World Cohort of Metastatic Colorectal Cancer. Cancers. 15(14). 3578–3578. 1 indexed citations

Duran, Goretti, Raquel Cruz, Francisco Barros, et al.. (2020). Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics?. Journal of Chemotherapy. 32(6). 310–322. 8 indexed citations

Salgado, Mercedes, et al.. (2019). First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial. Clinical & Translational Oncology. 22(4). 495–502. 8 indexed citations

Vidal, Joana, Alba Dalmases, Frederick S. Jones, et al.. (2017). Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Annals of Oncology. 28(6). 1325–1332. 255 indexed citations

Alonso‐Alconada, Lorena, Jorge Barbazán, Sonia Candamio, et al.. (2017). PrediCTC, liquid biopsy in precision oncology: a technology transfer experience in the Spanish health system. Clinical & Translational Oncology. 20(5). 630–638. 3 indexed citations

Dalmases, Alba, Alicia Abalo, Mar Iglesias, et al.. (2016). Accuracy of plasma RAS mutation testing for therapy selection and monitoring of colorectal cancer patients. Annals of Oncology. 27. vi176–vi176. 1 indexed citations

Barbazán, Jorge, Laura Muinelo‐Romay, María Vieito, et al.. (2014). A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer. International Journal of Cancer. 135(11). 2633–2643. 53 indexed citations

Grande, Carlos, Sonia Candamio, María José Villanueva, et al.. (2013). Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer. Journal of Geriatric Oncology. 4(2). 114–121. 11 indexed citations

10.

Barbazán, Jorge, María Vieito, Alicia Abalo, et al.. (2012). A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer. Journal of Cellular and Molecular Medicine. 16(10). 2342–2349. 19 indexed citations

11.

Barbazán, Jorge, Lorena Alonso‐Alconada, Laura Muinelo‐Romay, et al.. (2012). Molecular Characterization of Circulating Tumor Cells in Human Metastatic Colorectal Cancer. PLoS ONE. 7(7). e40476–e40476. 68 indexed citations

12.

Lamas, María Jesús, et al.. (2012). The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens. Cancer Chemotherapy and Pharmacology. 69(6). 1591–1599. 21 indexed citations

13.

Barbazán, Jorge, Lorena Alonso‐Alconada, Laura Muinelo‐Romay, et al.. (2012). Molecular characterization of circulating tumor cells in human metastatic colorectal cancer.. Journal of Clinical Oncology. 30(15_suppl). 10534–10534. 2 indexed citations

14.

Salgado, Mercedes, et al.. (2010). A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer. British Journal of Cancer. 103(10). 1536–1541. 12 indexed citations

15.

Cueva, Juan, Marcos Mecías‐Calvo, Urbano Anido, et al.. (2010). Methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel: results of a pilot study. Investigational New Drugs. 30(2). 688–694. 7 indexed citations

16.

Salgado, Mercedes, Manuel Valladares‐Ayerbes, Ana M. Carballo, et al.. (2010). Efficacy of epoetin-beta 30,000 IU/week in correcting anaemia in patients with gastrointestinal tumours subjected to concomitant chemoradiotherapy. Clinical & Translational Oncology. 12(12). 843–848. 2 indexed citations

17.

Lamas, María Jesús, Goretti Duran, Urbano Anido, et al.. (2010). Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin (mFOLFOX6) regimen in patients with metastatic colorectal cancer.. Journal of Clinical Oncology. 28(15_suppl). e13504–e13504.

18.

Grande, Carlos, J. R. Mel, Sonia Candamio, et al.. (2009). Phase II study of biweekly XELOX (capecitabine and oxaliplatin) as first line chemotherapy in elderly patients with metastatic colorectal cancer. Journal of Clinical Oncology. 27(15_suppl). e15053–e15053. 2 indexed citations

19.

Grande, Carlos, J. R. Mel, Mercedes Salgado, et al.. (2006). Multicenter phase II study of cetuximab and irinotecan as third line chemotherapy in patients (pts) with metastatic colorectal cancer (MCRC) previously treated with both irinotecan and oxaliplatin regimens. Journal of Clinical Oncology. 24(18_suppl). 13551–13551. 2 indexed citations

20.

Barón-López, Francisco Javier, Begoña Graña, Teresa Curiel, et al.. (2001). Gemcitabine plus vinorelbine for the treatment of advanced non-small cell lung cancer. European Journal of Cancer. 37(11). 1381–1384. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact